Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 1
1948 2
1949 3
1952 1
1953 4
1954 2
1955 2
1956 5
1957 3
1958 4
1959 3
1960 6
1961 6
1962 12
1963 27
1964 24
1965 21
1966 16
1967 16
1968 9
1969 9
1970 13
1971 15
1972 7
1973 14
1974 15
1975 22
1976 13
1977 12
1978 5
1979 20
1980 18
1981 14
1982 26
1983 30
1984 25
1985 32
1986 27
1987 33
1988 37
1989 28
1990 39
1991 40
1992 38
1993 75
1994 41
1995 63
1996 70
1997 59
1998 59
1999 68
2000 74
2001 79
2002 97
2003 76
2004 89
2005 112
2006 125
2007 115
2008 117
2009 131
2010 164
2011 200
2012 225
2013 277
2014 286
2015 305
2016 350
2017 402
2018 463
2019 487
2020 2699
2021 2037
2022 1175
2023 112
Text availability
Article attribute
Article type
Publication date

Search Results

10,108 results
Results by year
Filters applied: . Clear all
Page 1
Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C, Moroni G. Ponticelli C, et al. Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14. Expert Opin Drug Saf. 2017. PMID: 27927040 Review.
Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH. ...
Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functi
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB, Dash AP. Nina PB, et al. Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20. Indian J Public Health. 2020. PMID: 32496241 Free article. Review.
Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). ...
Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). ...
Of chloroquine and COVID-19.
Touret F, de Lamballerie X. Touret F, et al. Antiviral Res. 2020 May;177:104762. doi: 10.1016/j.antiviral.2020.104762. Epub 2020 Mar 5. Antiviral Res. 2020. PMID: 32147496 Free PMC article. Review.
The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR. Martinez GP, et al. Curr Pharm Des. 2020;26(35):4467-4485. doi: 10.2174/1381612826666200707132920. Curr Pharm Des. 2020. PMID: 32634079 Review.
Chloroquine (CQ) and hydroxychloroquine (HCQ) are derivatives of the heterocyclic aromatic compound quinoline. ...
Chloroquine (CQ) and hydroxychloroquine (HCQ) are derivatives of the heterocyclic aromatic compound quinoline. ...
Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.
Udupa A, Leverenz D, Balevic SJ, Sadun RE, Tarrant TK, Rogers JL. Udupa A, et al. Curr Allergy Asthma Rep. 2021 Jan 21;21(1):5. doi: 10.1007/s11882-020-00983-9. Curr Allergy Asthma Rep. 2021. PMID: 33475900 Free PMC article. Review.
This is, at least in part, due to the wide variability in hydroxychloroquine pharmacokinetics between patients and difficulty achieving adequate target tissue concentrations of hydroxychloroquine without encountering unacceptable toxicities. ...Despite overall negat …
This is, at least in part, due to the wide variability in hydroxychloroquine pharmacokinetics between patients and difficulty achievi …
[Hydroxychloroquine for autoimmune diseases].
Danza Á, Graña D, Goñi M, Vargas A, Ruiz-Irastorza G. Danza Á, et al. Rev Med Chil. 2016 Feb;144(2):232-40. doi: 10.4067/S0034-98872016000200012. Rev Med Chil. 2016. PMID: 27092678 Free article. Review. Spanish.
Hydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. ...
Hydroxychloroquine (HCQ) is by far the most frequently used antimalarial for the management of Systemic Autoimmune Diseases. ...
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.
Bansal P, Goyal A, Cusick A 4th, Lahan S, Dhaliwal HS, Bhyan P, Bhattad PB, Aslam F, Ranka S, Dalia T, Chhabra L, Sanghavi D, Sonani B, Davis JM 3rd. Bansal P, et al. Ann Med. 2021 Dec;53(1):117-134. doi: 10.1080/07853890.2020.1839959. Ann Med. 2021. PMID: 33095083 Free PMC article. Review.
The purpose of this review is to elaborate on the mechanisms surrounding hydroxychloroquine. The review is an in-depth analysis of the antimalarial, immunomodulatory, and antiviral mechanisms of hydroxychloroquine, with detailed and novel pictorial explanations. ... …
The purpose of this review is to elaborate on the mechanisms surrounding hydroxychloroquine. The review is an in-depth analysis of th …
Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms.
Ferreira PMP, Sousa RWR, Ferreira JRO, Militão GCG, Bezerra DP. Ferreira PMP, et al. Pharmacol Res. 2021 Jun;168:105582. doi: 10.1016/j.phrs.2021.105582. Epub 2021 Mar 26. Pharmacol Res. 2021. PMID: 33775862 Review.
Chloroquine (CQ) and hydroxychloroquine (HCQ) are the most common drugs used to relieve acute and chronic inflammatory diseases. ...
Chloroquine (CQ) and hydroxychloroquine (HCQ) are the most common drugs used to relieve acute and chronic inflammatory diseases. ...
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE Jr, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysse CA, Weissman A, Yealy DM, Thompson BT, Brown SM; National Heart, Lung, and Blood Institute PETAL Clinical Trials Network; Steingrub J, Smithline H, Tiru B, Tidswell M, Kozikowski L, Thornton-Thompson S, De Souza L, Hou P, Baron R, Massaro A, Aisiku I, Fredenburgh L, Seethala R, Johnsky L, Riker R, Seder D, May T, Baumann M, Eldridge A, Lord C, Shapiro N, Talmor D, O’Mara T, Kirk C, Harrison K, Kurt L, Schermerhorn M, Banner-Goodspeed V, Boyle K, Dubosh N, Filbin M, Hibbert K, Parry B, Lavin-Parsons K, Pulido N, Lilley B, Lodenstein C, Margolin J, Brait K, Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu K, Kangelaris K, Wang R, Calfee C, Yee K, Hendey G, Chang S, Lim G, Qadir N, Tam A, Beutler R, Levitt J, Wilson J, Rogers A, Vojnik R, Roque J, Albertson T, Chenoweth J, Adams J, Pearson S, Juarez M, Almasri E, Fayed M, Hughes A, Hillard S, Huebinger R, Wang H, Vidales E, Patel B, Ginde A, Moss M, Baduashvili A, McKeehan J, Finck L, Higgins C, Howell M, Douglas I, Haukoos J, Hiller T, Lyle C, Cupelo A, Caruso E, Camacho C, Gravitz S, Finigan J, Griesmer C, Park P, Hyzy R, Nelson K, McDonough K, Olbrich N, Williams M, Kapoor R, Nash J, Willig M, Ford H, Gardner-Gray J, Ramesh M, Moses M, Ng Gong M, Aboodi M, Asghar A, Amosu O, Torres M, Kaur S, Chen JT, Hope A, Lopez B, Rosales K, Young You J, Mosier J, Hypes C, Natt B, Borg B, Salvagio Campbell E, Hite RD, Hudock K, Cresie A, Alhasan F, Gomez-Arroyo J, Duggal A, Mehkri O, Hastings A, Sahoo D, Abi Fadel F, Gole S, Shaner V, Wimer A, Meli Y, King A, Terndrup T, Exline M, Pannu S, Robart E, Karow S, Hough C, Robinson B, Johnson N, Henning D, Campo M, Gundel S, Seghal S, Katsandres S, Dean S, Khan A, Krol O, Jouzestani M, Huynh P, Weissman A, Yealy D, Scholl D, Adams P, McVerry B, Huang D, Angus D, Schooler J, Moore S, Files C, Miller C, Gibbs K, LaRose M, Flores L, Koehler L, Morse C, Sanders J, Langford C, Nanney K, MdalaGausi M, Yeboah P, Morris P, Sturgill J, Seif S, Cassity E, Dhar S, de Wit M, Mason J, Goodwin A, Hall G, Grady A, Chamberlain A, Brown S, Bledsoe J, Leither L, Peltan I, Starr N, Fergus M, Aston V, Montgomery Q, Smith R, Merrill M, Brown K, Armbruster B, Harris E, Middleton E, Paine R, Johnson S, Barrios M, Eppensteiner J, Limkakeng A, McGowan L, Porter T, Bouffler A, Leahy JC, deBoisblanc B, Lammi M, Happel K, Lauto P, Self W, Casey J, Semler M, Collins S, Harrell F, Lindsell C, Rice T, Stubblefield W, Gray C, Johnson J, Roth M, Hays M, Torr D, Zakaria A, Schoenfeld D, Thompson T, Hayden D, Ringwood N, Oldmixon C, Ulysse C, Morse R, Muzikansky A, Fitzgerald L, Whitaker S, Lagakos A, Brower R, Reineck L, Aggarwal N, Bienstock K, Freemer M, Maclawiw M, Weinmann G, Morrison L, Gillespie M, Kryscio R, Brodie D, Zareba W, Rompalo A, Boeckh M, Parsons P, Christie J, Hall J, Horton N, Zoloth L, Dickert N, Diercks D. Self WH, et al. JAMA. 2020 Dec 1;324(21):2165-2176. doi: 10.1001/jama.2020.22240. JAMA. 2020. PMID: 33165621 Free PMC article. Clinical Trial.
IMPORTANCE: Data on the efficacy of hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) are needed. OBJECTIVE: To determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19. ...
IMPORTANCE: Data on the efficacy of hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) are needed. OBJECTIVE …
10,108 results
You have reached the last available page of results. Please see the User Guide for more information.